Bonate, Peter L <br/><br/>
Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  Jul 2013 
 - 231-40 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1432-0843 
<br/><br/><label>Standard No.: </label>10.1007/s00280-013-2191-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--therapeutic use<br/>Carcinoma, Renal Cell--drug therapy<br/>Combined Modality Therapy<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Indazoles<br/>Kidney--drug effects<br/>Kidney Neoplasms--drug therapy<br/>Kinetics<br/>Logistic Models<br/>Male<br/>Middle Aged<br/>Models, Biological<br/>Pharmacogenetics--methods<br/>Pyrimidines--therapeutic use<br/>Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors<br/>Sulfonamides--therapeutic use<br/>Tumor Burden--drug effects